iBio (IBIO) Receivables (2011 - 2025)

iBio (IBIO) posted quarterly Receivables of $65000.0 for Q3 2025, down 98.74% quarter-over-quarter from $5.2 million in Q1 2023.

iBio (IBIO) Receivables (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Receivables for 14 consecutive years, with $65000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Receivables changed N/A year-over-year to $65000.0; the TTM figure through Sep 2025 stood at $65000.0 (changed N/A YoY), while the FY2023 annual figure was $204000.0, down 96.66% from the prior year.
Receivables eased to $65000.0 in Q3 2025 per IBIO's latest filing, from $5.2 million in the prior quarter.
Across five years, Receivables topped out at $10.6 million in Q2 2021 and bottomed at $65000.0 in Q3 2025.
Historically, Receivables has averaged $4.6 million across 4 years, with a median of $5.3 million in 2021.
Annual changes were most pronounced in 2021 — Receivables surged 2146.12% — and 2022, when it slumped 90.59%.
iBio's Receivables stood at $5.2 million in 2021, then grew by 16.48% to $6.1 million in 2022, then dropped by 14.83% to $5.2 million in 2023, then slumped by 98.74% to $65000.0 in 2025.
Business Quant data shows IBIO's Receivables at $65000.0 in Q3 2025, $5.2 million in Q1 2023, and $6.1 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data